We are working with the Tajikistan Ministry of Health and Social Protection to diagnose and treat children with drug-resistant tuberculosis (DR-TB).

Where possible, we aim to treat TB patients at home and demonstrate that the comprehensive TB care model is feasible. This includes patient follow-up, active testing for new patients, laboratory diagnosis, individualised treatment and psychosocial support (including play therapy). 

In the south of the country, we run the Zero TB project in Kulob, aiming for TB elimination. This project focuses on TB prevention and care in households, places where people seek care and where they work. 

We have also started working in the penitentiary system with the aim of improving the quality of TB care and other comorbidities in the central prison hospital and strengthening TB screening in prisons and pre-trial detention facilities. 


Our activities in 2022 in Tajikistan

Data and information from the International Activity Report 2022.

MSF IN TAJIKISTAN IN 2022 Tuberculosis (TB) is the focus of Doctors Without Borders (MSF) activities in Tajikistan. We provide comprehensive care for both children and adults, with the aim of reducing TB incidence and death rates.

As well as diagnosis and treatment, we offer patients adherence counselling and health education and call for greater access to care across the country.

Our teams continue to implement the innovative F-DOT (family directly observed therapy) approach, which allows patients to take their medication at home under the supervision of a family member. We also conduct contact tracing to ensure early TB detection and treatment for relatives of TB patients and for people in the Tajik penitentiary system.

In 2022, MSF began TB screening and diagnosis in several prison colonies and one pre-trial detention centre. This service is available for all people entering and leaving these institutions, including detainees and penitentiary system workers.

In the ‘Zero TB’ project in Kulob district, which aims to demonstrate the feasibility of eliminating TB, we launched the SMARRTT (six-month all-oral regimens for rifampicin-resistant TB treatment) operational study. This followed the successful conclusion of the TB-PRACTECAL clinical trial and the most recent recommendations from the World Health Organization on all-oral, shorter regimens for people with drug-resistant TB.

In September, following violent clashes at the border between Kyrgyzstan and Tajikistan, we sent a team to Isfara district to support the local hospitals with donations of medical supplies and distribute food and hygiene kits to displaced people.

IN 2022

Filter Tips
  • Try a different country, year, format, or topic.
  • Clear one or more filters